Vedtægter

March 16, 2018 05:54 ET | Source: ALK Abello ALK Abello

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF)

Vedtægter vedtaget på den ordinære generalforsamling i ALK den 12. marts 2018

ALK Vedtægter_12032018_final

Attachments

ALK Vedtægter_12032018_final

ALK Vedtægter_12032018_final...

Recommended Reading

June 15, 2026 03:00 ET | Source: ALK Abello

EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis

ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy® 1 mg, the first and only needle-free adrenaline treatment for...
Read More
June 11, 2026 03:00 ET | Source: ALK Abello

Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1HCP survey data...
Read More